

## **Bapcor Limited**

(ASX: BAP)

#### **ASX** Release

25 September 2018

#### **Vesting of Performance Rights**

Bapcor Limited (the **Company**) attaches an Appendix 3B reflecting changes in its issued capital, due to the vesting of Performance Rights previously issued in FY16 and FY17 to senior executives under the Company's Long Term Incentive Plan (**LTIP**).

Each Performance Right entitles its holder to acquire one fully paid ordinary share in the Company if the applicable performance hurdles are met at the end of the relevant performance periods, being 30 June 2018. The performance hurdles are based on the Company's total shareholder return (**TSR**) relative to the TSR of peer group companies, and the Company's compound annual growth rate in earnings per share (**EPS**).

The achievement of the performance hurdles was independently tested by a third party against the Company's TSR and EPS performance over the applicable performance period. The extent to which the Performance Rights have vested is as follows:

- **FY16 Performance Rights**: Based on the Company's TSR and EPS performance for the three years ended 30 June 2018, 100% of the FY16 Performance Rights on issue (370,308 in total) have vested.
- FY17 Performance Rights: Based on the Company's TSR performance for the two years ended 30 June 2018, 97.2% of the FY17 Performance Rights on issue linked to the TSR performance hurdle have vested. Based on the Company's EPS performance for the two years ended 30 June 2018, 100% of the FY17 Performance Rights on issue linked to the EPS performance hurdle have vested. As a result, a total of 120,693 FY17 Performance Rights have vested, and 2,156 FY17 Performance Rights have lapsed.

Further details on the Performance Rights and their performance hurdles are provided in the Company's 2018 Remuneration Report.

A total of **491,001** underlying shares for the vested Performance Rights have been acquired on-market by Bapcor's Employee Share Trust, and transferred to the Performance Rights holders; these shares will be subject to a 12-month escrow period.

No new Bapcor shares have been issued upon the vesting of the Performance Rights.

#### -ENDS-

For further information, please contact:

Darryl Abotomey
Managing Director and CEO
Bapcor Limited
+61 419 838 059
+61 3 9914 5555

Gregory Fox CFO and Company Secretary Bapcor Limited +61 417 562 891 +61 3 9914 5555

Rule 2.7, 3.10.3, 3.10.4, 3.10.5

# **Appendix 3B**

### New issue announcement, application for quotation of additional securities and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/1. 04/03/13		
Name	of entity	
Варсо	r Limited (Bapcor or the Company	
ABN		
ABN 8	30 153 199 912	
We (th	ne entity) give ASX the following info	ormation.
	t 1 - All issues ust complete the relevant sections (attac	ch sheets if there is not enough space).
1	*Class of *securities issued or to be issued	N/A
2	Number of +securities issued or	Nil.
2	to be issued (if known) or maximum number which may be issued	The number of Performance Rights on issue has decreased due to vesting.
		The underlying shares for the vested Performance Rights have been acquired on-market by Bapcor's Employee Share Trust, and transferred to the Performance Rights holders.
		No new shares have been issued.
_		
3	Principal terms of the *securities (e.g. if options, exercise price and expiry date; if partly paid *securities, the amount outstanding and due dates for payment; if *convertible securities, the conversion price and dates for conversion)	N/A

04/03/2013 Appendix 3B Page 1

<sup>+</sup> See chapter 19 for defined terms.

4	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	
5	Issue price or consideration	N/A
6	Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)	N/A
6a	Is the entity an *eligible entity that has obtained security holder approval under rule 7.1A?	No
	If Yes, complete sections 6b – 6h in relation to the *securities the subject of this Appendix 3B, and comply with section 6i	
6b	The date the security holder resolution under rule 7.1A was passed	N/A
6c	Number of *securities issued without security holder approval under rule 7.1	N/A
6d	Number of *securities issued with security holder approval under rule 7.1A	N/A
6e	Number of *securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)	N/A

Appendix 3B Page 2 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

6f	Number of *securities issued under an exception in rule 7.2	N/A	
6g	If *securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the *issue date and both values. Include the source of the VWAP calculation.	N/A	
6h	If *securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements	N/A	
6i	Calculate the entity's remaining	See Annexure 1	
OI .	issue capacity under rule 7.1 and rule 7.1A — complete Annexure 1 and release to ASX Market Announcements	Oce Affilexate 1	
7	+Issue dates	N/A	
,	Note: The issue date may be prescribed by ASX (refer to the definition of issue date in rule 19.12). For example, the issue date for a pro rata entitlement issue must comply with the applicable timetable in Appendix 7A.  Cross reference: item 33 of Appendix 3B.		
		Number	+Class
8	Number and +class of all +securities quoted on ASX (including the +securities in section 2 if applicable)	280,244,752	Fully paid ordinary shares
		Number	+Class
9	Number and *class of all *securities not quoted on ASX (including the *securities in section 2 if applicable)	979,314	Performance Rights issued under Bapcor's Long Term Incentive Plan
	<b>5</b>	L 11/A	
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	

o4/o3/2013 Appendix 3B Page 3

<sup>+</sup> See chapter 19 for defined terms.

## Part 2 - Pro rata issue

11	Is security holder approval required?	N/A
12	Is the issue renounceable or non-renounceable?	N/A
13	Ratio in which the *securities will be offered	N/A
14	*Class of *securities to which the offer relates	N/A
15	*Record date to determine entitlements	N/A
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	N/A
17	Policy for deciding entitlements in relation to fractions	N/A
18	Names of countries in which the entity has security holders who will not be sent new offer documents	N/A
	Note: Security holders must be told how their entitlements are to be dealt with.  Cross reference: rule 7.7.	
19	Closing date for receipt of acceptances or renunciations	N/A
20	Names of any underwriters	N/A
21	Amount of any underwriting fee or commission	N/A
22	Names of any brokers to the issue	N/A
23	Fee or commission payable to the broker to the issue	N/A
24	Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of security holders	N/A

Appendix 3B Page 4 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

25	If the issue is contingent on security holders' approval, the date of the meeting	N/A
26	Date entitlement and acceptance form and offer documents will be sent to persons entitled	N/A
27	If the entity has issued options, and the terms entitle option holders to participate on exercise, the date on which notices will be sent to option holders	N/A
28	Date rights trading will begin (if applicable)	N/A
29	Date rights trading will end (if applicable)	N/A
30	How do security holders sell their entitlements in full through a broker?	N/A
31	How do security holders sell <i>part</i> of their entitlements through a broker and accept for the balance?	N/A
32	How do security holders dispose of their entitlements (except by sale through a broker)?	N/A
33	*Issue date	N/A
Dar <del>t</del>	3 - Quotation of secu	uritios
	d only complete this section if you are a	
34	Type of *securities (tick one)	
(a)	*Securities described in Pa	rt 1
(b)		end of the escrowed period, partly paid securities that become fully paid ten restriction ends, securities issued on expiry or conversion of convertible

04/03/2013 Appendix 3B Page 5

<sup>+</sup> See chapter 19 for defined terms.

## Entities that have ticked box 34(a)

## Additional securities forming a new class of securities

Tick to docum	o indicate you are providing the informati nents	ion or
35	If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders	
36	· · · ·	securities, a distribution schedule of the additional umber of holders in the categories
37	A copy of any trust deed for	the additional *securities
Entiti	ies that have ticked box 34	(b)
38	Number of *securities for which *quotation is sought	N/A
39	*Class of *securities for which quotation is sought	N/A
40	Do the *securities rank equally in all respects from the *issue date with an existing *class of quoted *securities?	N/A
	If the additional *securities do not rank equally, please state:  • the date from which they do  • the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment  • the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment	

Appendix 3B Page 6 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

41	Reason for request for quotation now	N/A
	Example: In the case of restricted securities, end of restriction period	
	(if issued upon conversion of another *security, clearly identify that other *security)	

42 Number and \*class of all \*securities quoted on ASX (including the \*securities in clause 38)

Number	+Class
N/A	

o4/o3/2013 Appendix 3B Page 7

<sup>+</sup> See chapter 19 for defined terms.

#### **Quotation agreement**

- \*Quotation of our additional \*securities is in ASX's absolute discretion. ASX may quote the \*securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the \*securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those \*securities should not be granted \*quotation.
  - An offer of the +securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the \*securities to be quoted under section 1019B of the Corporations Act at the time that we request that the \*securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document is not available now, we will give it to ASX before +quotation of the \*securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Gregory Fox **Company Secretary** 

25 September 2018

+ See chapter 19 for defined terms.

Appendix 3B Page 8 04/03/2013

# Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for eligible entities

Introduced 01/08/12 Amended 04/03/13

## Part 1

Rule 7.1 – Issues exceeding 15% of capital		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Insert number of fully paid +ordinary securities on issue 12 months before the +issue date or date of agreement to issue	278,633,080	
<ul> <li>Add the following:</li> <li>Number of fully paid <sup>+</sup>ordinary securities issued in that 12 month period under an exception in rule 7.2</li> </ul>	932,347 shares issued on 29 September 2017 679,325 shares issued on 27 April 2018	
Number of fully paid <sup>+</sup> ordinary securities issued in that 12 month period with shareholder approval		
Number of partly paid <sup>+</sup> ordinary securities that became fully paid in that 12 month period		
Note: Include only ordinary securities here – other classes of equity securities cannot be added Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed It may be useful to set out issues of securities on different dates as separate line items		
Subtract the number of fully paid +ordinary securities cancelled during that 12 month period	Nil	
"A"	280,244,752	

o4/o3/2013 Appendix 3B Page 9

<sup>+</sup> See chapter 19 for defined terms.

Step 2: Calculate 15% of "A"		
"B"	0.15	
	[Note: this value cannot be changed]	
<b>Multiply</b> "A" by 0.15	42,036,713	
Step 3: Calculate "C", the amount of placement capacity under rule 7.1 that has already been used		
Insert number of *equity securities issued or agreed to be issued in that 12 month period not counting those issued:		
• Under an exception in rule 7.2		
Under rule 7.1A		
<ul> <li>With security holder approval under rule 7.1 or rule 7.4</li> </ul>		
Note:  This applies to equity securities, unless specifically excluded – not just ordinary securities  Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed  It may be useful to set out issues of securities on different dates as separate line items		
"C"	0	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15	42,036,713	
Note: number must be same as shown in Step 2		
Subtract "C"	0	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	42,036,713	
	[Note: this is the remaining placement capacity under rule 7.1]	

Appendix 3B Page 10 04/03/2013

<sup>+</sup> See chapter 19 for defined terms.

## Part 2

Rule 7.1A – Additional placement capacity for eligible entities		
Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
"A"	N/A	
Note: number must be same as shown in Step 1 of Part 1		
Step 2: Calculate 10% of "A"		
"D"	0.10	
	Note: this value cannot be changed	
<b>Multiply</b> "A" by 0.10		
Step 3: Calculate "E", the amount of pla has already been used	acement capacity under rule 7.1A that	
Insert number of *equity securities issued or agreed to be issued in that 12 month period under rule 7.1A  Notes: This applies to equity securities – not just ordinary securities Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained It may be useful to set out issues of securities on different dates as separate line items		
Step 4: Subtract "E" from ["A" x "D' capacity under rule 7.1A	'] to calculate remaining placement	
"A" x 0.10		
Note: number must be same as shown in Step 2		
Subtract "E"		
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.10] – "E"		
	Note: this is the remaining placement capacity under rule 7.1A	

<sup>+</sup> See chapter 19 for defined terms.

04/03/2013 Appendix 3B Page 11